

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	3662661
<b>Application Number:</b>	10501317
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	6119
<b>Title of Invention:</b>	Cyclic urea derivatives with 5-ht2c receptor activity
<b>First Named Inventor/Applicant Name:</b>	Steven M Bromidge
<b>Customer Number:</b>	20462
<b>Filer:</b>	Kathryn Lutomski Sieburth/Mary Fenerty
<b>Filer Authorized By:</b>	Kathryn Lutomski Sieburth
<b>Attorney Docket Number:</b>	32969
<b>Receipt Date:</b>	23-JUL-2008
<b>Filing Date:</b>	22-FEB-2005
<b>Time Stamp:</b>	13:21:51
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 930
RAM confirmation Number	10402
Deposit Account	192570
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	RCE_Transmittal_Letter.pdf	83125	no	1
			06bd8537c132d5ce4463173503d6762 bef94714e		

### Warnings:

This is not a USPTO supplied RCE SB30 form.

### Information:

2		Amendment_and_Extension _of_Time.pdf	369109	yes	8
			9d36ea1cb4b301bd47328014a34061a 9b47d9781		

### Multipart Description/PDF files in .zip description

	Document Description	Start	End
	Amendment - After Non-Final Rejection	1	1
	Claims	2	5
	Applicant Arguments/Remarks Made in an Amendment	6	8

### Warnings:

### Information:

3	Information Disclosure Statement Letter	Supplemental_IDS_Letter.pdf	48408	no	1
			4b9859dc41b54168aab422510c3784b 39fc1ca1e		

### Warnings:

### Information:

4	Information Disclosure Statement (IDS) Filed	1449_Form.pdf	55654	no	1
			0fbda0854ed0f28a7478bca29157d810 24a9082d		

### Warnings:

### Information:

This is not an USPTO supplied IDS fillable form

5	Foreign Reference	1WO9404533A1.pdf	2458530	no	55
			abfd8efd0c00ad0ce936602b842b78ec 4ace9b23		

### Warnings:

### Information:

6	NPL Documents	3Loo_Int_Clin_Psychopharm_2002.pdf	162771	no	9
			9e480ceb818696ec50ab5ecd249c7ea4d2609707		
Warnings:					
Information:					
7	NPL Documents	4Papp_Neuropsychopharmacology_2003.pdf	285453	no	10
			b98defc930ffc0608835096e272b2b439a572236		
Warnings:					
Information:					
8	NPL Documents	5Cremers_Neuropsychopharmacology_2004.pdf	185230	no	8
			76b32ff18076d0570067b4f9fd64c7cd4330f25		
Warnings:					
Information:					
9	NPL Documents	6Dremencov_Neuropharmacology_2005.pdf	299030	no	9
			f622b38e91a2cb750d704d6ced9c53be30c5559c		
Warnings:					
Information:					
10	NPL Documents	8OA_10511769_3_10_08.pdf	238456	no	5
			1792c33973830f5592a5271a6b176d99cac78a98		
Warnings:					
Information:					
11	NPL Documents	2Jenck_Exp_Opin_Invest_Drugs_1998.pdf	1343807	no	13
			27a46faee2481e96ae6a13b6a7cce114d88d71c5		
Warnings:					
Information:					
12	NPL Documents	7Goodacre_BOMCL_2005.pdf	373831	no	5
			6d1aadcc6b0c3cd5dfe702e3026c19ac36eb888a		
Warnings:					
Information:					
13	Fee Worksheet (PTO-06)	fee-info.pdf	8340	no	2
			ed47b1d9f4021b1a83ff06f8741e52ad45d4b789		
Warnings:					
Information:					
Total Files Size (in bytes):			5911744		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.